Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular diagnostics of myeloproliferative neoplasms.
Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, Percy MJ, Porret N, Palmqvist L, Schwarz J, McMullin MF, Schnittger S, Pallisgaard N, Hermouet S; MPN&MPNr-EuroNet. Langabeer SE, et al. Among authors: oppliger leibundgut e. Eur J Haematol. 2015 Oct;95(4):270-9. doi: 10.1111/ejh.12578. Epub 2015 May 18. Eur J Haematol. 2015. PMID: 25951317 Review.
Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature.
Bürki S, Shumilov E, Bonadies N, Flach J, Legros M, Banz Y, Oppliger-Leibundgut E, Fiedler M, Angelillo-Scherrer A, Rovo A, Bacher U. Bürki S, et al. Among authors: oppliger leibundgut e. Leuk Lymphoma. 2018 Sep;59(9):2233-2237. doi: 10.1080/10428194.2017.1416367. Epub 2018 Jan 3. Leuk Lymphoma. 2018. PMID: 29295644 Review. No abstract available.
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
Froesch P, Mark M, Rothschild SI, Li Q, Godar G, Rusterholz C, Oppliger Leibundgut E, Schmid S, Colombo I, Metaxas Y, König D, Sessa C, Gautschi O, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Froesch P, et al. Among authors: oppliger leibundgut e. Lung Cancer. 2021 Jun;156:91-99. doi: 10.1016/j.lungcan.2021.04.002. Epub 2021 Apr 25. Lung Cancer. 2021. PMID: 33933896 Clinical Trial.
Pleural tumors as sole primary manifestation of acute promyelocytic leukemia.
Mueller BU, Buerger AU, Solenthaler M, Garamvoelgyi EM, Oppliger-Leibundgut E, Fey MF, Pabst T. Mueller BU, et al. Among authors: oppliger leibundgut e. Ann Oncol. 2006 Apr;17(4):722-3. doi: 10.1093/annonc/mdj062. Epub 2005 Nov 15. Ann Oncol. 2006. PMID: 16291581 Free article. No abstract available.
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E, Froesch P, Stahel R, Hess T, Rauch D, Schmid P, Mayer M, Crowe S, Brauchli P, Ribi K, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Zappa F, et al. Among authors: oppliger leibundgut e. Lung Cancer. 2012 Dec;78(3):239-44. doi: 10.1016/j.lungcan.2012.08.017. Epub 2012 Sep 23. Lung Cancer. 2012. PMID: 23009726 Clinical Trial.
A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL).
Novak U, Oppliger Leibundgut E, Hager J, Mühlematter D, Jotterand M, Besse C, Leupin N, Ratschiller D, Papp J, Kearsey G, Aebi S, Graber H, Jaggi R, Lüthi JM, Meyer-Monard S, Lathrop M, Tobler A, Fey MF. Novak U, et al. Among authors: oppliger leibundgut e. Blood. 2002 Sep 1;100(5):1787-94. Blood. 2002. PMID: 12176901 Free article.
31 results